Target/therapies for chronic recurrent erythema nodosum leprosum.
Animals
Anti-Inflammatory Agents
/ adverse effects
Chronic Disease
Erythema Nodosum
/ diagnosis
Humans
Inflammation Mediators
/ antagonists & inhibitors
Leprostatic Agents
/ adverse effects
Leprosy, Lepromatous
/ diagnosis
Molecular Targeted Therapy
Recurrence
Selective Serotonin Reuptake Inhibitors
/ adverse effects
Stress, Psychological
/ drug therapy
Antidiabetic
erythema nodosum leprosum
lepra reaction
pharmacology
stress
targets
Journal
Indian journal of pharmacology
ISSN: 1998-3751
Titre abrégé: Indian J Pharmacol
Pays: India
ID NLM: 7902477
Informations de publication
Date de publication:
Historique:
received:
12
12
2019
revised:
12
02
2020
accepted:
25
03
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
14
7
2021
Statut:
ppublish
Résumé
A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.
Identifiants
pubmed: 32874007
doi: 10.4103/ijp.IJP_788_19
pii: IJPharm-52-222
pmc: PMC7446680
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Inflammation Mediators
0
Leprostatic Agents
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-226Informations de copyright
Copyright: © 2020 Indian Journal of Pharmacology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Chest. 2000 Aug;118(2):503-8
pubmed: 10936147
Transl Res. 2015 Nov;166(5):451-8
pubmed: 26141671
Neuropharmacology. 2013 Apr;67:304-17
pubmed: 23085335
Metabolism. 2010 Jun;59(6):887-95
pubmed: 20015525
Br J Pharmacol. 2011 Apr;162(7):1498-508
pubmed: 21091653
Int Immunopharmacol. 2013 May;16(1):85-92
pubmed: 23557965
Eur Heart J. 2002 Mar;23(5):376-83
pubmed: 11846495
J Biol Chem. 2014 Aug 15;289(33):23246-55
pubmed: 24973221
J Pharmacol Exp Ther. 2010 Jul;334(1):206-13
pubmed: 20371705
Chest. 2000 Apr;117(4):1162-72
pubmed: 10767254
Cardiovasc Res. 2008 Aug 1;79(3):360-76
pubmed: 18487233
Mayo Clin Proc. 2012 Jun;87(6):561-70
pubmed: 22677076
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9
pubmed: 16461893
Indian J Dermatol Venereol Leprol. 2013 Nov-Dec;79(6):739-49
pubmed: 24177605
Indian J Dermatol. 2014 Mar;59(2):166-8
pubmed: 24700936
Immune Netw. 2013 Aug;13(4):123-32
pubmed: 24009539
Intern Med. 2013;52(19):2179-87
pubmed: 24088749
Pharm Biol. 2016 Jul;54(7):1173-8
pubmed: 26305116
Atherosclerosis. 2012 Dec;225(2):403-7
pubmed: 23107042
Hypertension. 2006 Jun;47(6):1183-8
pubmed: 16636195
Cell Biol Int. 2007 Dec;31(12):1456-61
pubmed: 17689273
Am J Trop Med Hyg. 2006 May;74(5):868-79
pubmed: 16687695
Chin Med J (Engl). 2012 Oct;125(19):3440-4
pubmed: 23044303
Int J Lepr Other Mycobact Dis. 2004 Jun;72(2):125-33
pubmed: 15301592
Brain Behav Immun. 2012 Mar;26(3):469-79
pubmed: 22251606
Eur J Endocrinol. 2008 May;158(5):631-41
pubmed: 18426821
Expert Opin Pharmacother. 2012 Dec;13(18):2581-91
pubmed: 23121473
Eur J Pharmacol. 2014 Aug 15;737:77-84
pubmed: 24842192